in the iliac fossa, with dissection of iliac vessels and bladder dome, and ligatures with nonabsorbable sutures (cotton 4.0) and avoiding the use of electrocautery.
The graft was perfused with Euro-Collins ® or Belzer ® perfusion solutions for maintenance, followed by bench surgery with special care in the hilum region, and performing vascular and lymphatic ligatures with non-absorbable sutures (cotton 5.0). A triple therapy with azathioprine, prednisone and cyclosporin was used for immunosuppression. The diagnostic of acute cellular rejection was obtained by analysis of the clinical data, which included an increase in serum creatinine, a decrease in diuresis, eosinophilia and fever, after discarding vascular obstructions and urological disorders. A percutaneous renal biopsy was also obtained if needed to validate the diagnosis. Acute cellular rejections were treated with methylprednisolone (1g/day) for three days and monoclonal orthoclone antibody was used (OKT3) in corticoresistant rejection cases.
Pelvic ultrasonography was carried out routinely on the fifth postoperative day and whenever clinically necessary. The period for diagnosing lymphoceles by this imaging method was four to 93 postoperative days (average 35).
Lymphoceles were defined as the presence of perirenal fluid collection with a diameter greater than 5 cm, diagnosed after the first postoperative week. It was classified as symptomatic when associated to local and/or systemic signs and symptoms.
Surgical treatment was carried out in cases of symptomatic lymphocele with systemic repercussion. Surgical treatment was preceded by aspirative percutaneous puncture, guided by ultrasound, and also biochemical analysis and fluid culture.
Whenever there was evidence of lymphocele recurrence without signs of infection, internal drainage was performed (open or laparascopic peritoneal marsupialization). In case of infected lymphocele, external drainage was performed (closed drainage system). The average follow-up period was 24.5 months.
All results were submitted to statistical analysis using Fisher's exact test, considering a p-value < 0.05 as statistically significant.
RESULTS
Among the 170 kidney transplants studied, 106 patients (62.5%) developed acute cellular rejection and 19 (11.2%) had a diagnosis of lymphocele within an average period of 48.5 days (range 9 to 156). Table 1 shows that among the 19 patients that developed lymphocele, 16 (84%) had at least one episode of acute cellular rejection, and acute rejection was developed by 90 (59.6%) of the remaining 151 patients that did not present lymphocele. The relation found between lymphocele and rejection was statistically significant (p = 0.04). Among the sixteen patients with lymphocele that evolved with acute cellular rejection, ten (62.5%) were submitted to renal percutaneous biopsy with diagnostic confirmation. The acute cellular rejection had clinical manifestation between 3 to 50 days (average of 10 days) and the diagnosis of lymphocele occurred between the 7 th and the 64 th day post-surgery (average of 27.5 days).
Considering the 19 lymphoceles, 12 (63%) were symptomatic and needed surgical intervention, preceded by a negative culture in all cases. Thus, ultrasound guided percutaneous drainage was carried out in 7 patients (36.8%), marsupialization in 3 (15.7%), and laparoscopic marsupialization in 2 (10.5%). The remaining 7 asymptomatic patients (36.8%) were submitted to conservative treatment with ultrasound and laboratory test follow-up.
In three of the seven cases of symptomatic lymphoceles in which patients were submitted to percutaneous drainage, peritoneal marsupialization was necessary due to the development of recurrent fluid collection. Moreover, the method failed with recurrence of collection in two patients submitted to laparoscopic marsupialization. One of these patients was submitted to percutaneous drainage and the other to celiotomy ( Table 2 ).
The treatment developed favorably in 15 (78.9%) patients, 3 (15.8%) patients lost the graft due to immunological causes, and one (5.3%) died due a cause not related to the procedure. An average 24.5 month (range 3 to 53 months) follow-up period was maintained.
DISCUSSION
Kidney transplantation is currently the treatment of choice for patients in a terminal stage of chronic kidney failure. This is not, however, a procedure free of surgical complications. 3, 7 Lymphocele is a surgical complication with a described incidence between 0.6 and 18% of patients submitted to renal transplantation, presenting symptoms in 36% of cases with perirenal fluid collections above 100 ml.
1,2 The variation in frequency in different transplant centers may be justified by the absence of a standardized definition of complicated lymphocele, as the routine and early use of ultrasonography provides a diagnosis of lymphocele without clinical consequences.
5,8
The clinical observation that a significant proportion of the patients that presented acute cellular rejection had developed lymphocele suggests that there may be a direct association between these problems, which were considered statistically significant, but it has not yet been possible to establish any physiopathological cause directly related to these problems.
Data from the present study revealed a general incidence of 11.2% (19/170) of lymphocele after renal transplantation, of which 9.4% (16/170) had at least one episode of acute cellular rejection, and only 1.7% (3/170) presented lymphocele without acute rejection.
Braun et al 9 Another source of lymph is the three plexuses of the kidney graft. Two are intra-renal plexuses, one around the kidney tubules and another around the subcapsular region. The third is an extra-renal plexus, along the perirenal fat, which communicates with the intra-renal plexus that drains hilum branches into renal vessels running towards lateral aorta branches and paracava nodules. The ligation of lymphatic branches emerging from the graft hilum can thus be justified. 5 Excluding surgical factors, other causes of lymphocele are allograft biopsies, arteriovenous fistulas, use of diuretics, high doses of corticosteroids and anticoagulants, and especially episodes of acute cellular rejection. 5, 11 Renal allograft rejection is immunologically mediated and involves humoral and cellular response. Cellular rejection is more frequent in the first three months after transplantation, and is characterized by a set of signs and symptoms and impairment of kidney function. The rejection generally responds quickly and satisfactorily to corticosteroids, which in most cases revert the stimulated state of the autoimmune system that is manifested via intense inflammatory processes and increased local flow of effluents. 6, 12 A possible mechanism to explain the increased flow of lymph from the kidney during cellular rejection was demonstrated by Pedersen and Moris. 6 These authors used a sheep model in which the kidney was implanted in the neck of the animals. They recorded the flow of the effluent after cannulating lymph ducts of the graft. A 20 to 50 fold increase in flow was observed during rejection, in comparison to auto-transplant, indicating that an immunological factor related to the transplanted kidney may be involved in the genesis of the process. Castilho et al 11 observed episodes of cellular rejection before the diagnosis of lymphocele in 60% of patients studied, while Kauli et al 5 analyzed the risk factors involved statistically in lymphocele in 118 kidney transplants, and observed 6.8% symptomatic lymphoceles up to 3.7 years after transplantation. The latter authors concluded that only acute cellular rejection episodes were related to lymphocele diagnosis. The risk factors observed in the present study, such as the surgical technique and graft biopsy, did not show statistical significance when correlated to the physiopathology of lymphocele, with the exception of acute cellular rejection (P = 0.04) and possibly therapeutic use of corticosteroids ( Table 1) .
The data of the present study are similar to those of other reports which have shown an incidence of up to 75% of symptomatic lymphocele associated with episodes of cellular rejection treated with corticosteroids. 190 cases (49%) of perirenal collections, of which 98 patients (51%) were clinically asymptomatic and presented a volume below 50 ml that disappeared spontaneously during followup. The remaining patients (49%), presented collections between 51 and 100 ml and had associated or suspected symptoms of cellular rejection, demanding some type of surgical approach.
2,5
Whenever lymphocele is symptomatic, the size of the collection, the period of evolution and the symptoms should be considered, as well as excluding the presence of infection caused by previous puncture techniques. In the present study, we chose to perform surgery in 12 patients (63%) with symptomatic lymphocele, i.e. 7% of the kidney transplants.
According to Amante et al, 4 the treatment of choice for draining symptomatic lymphocele is peritoneal marsupialization, with a success rate between 80 and 90%. The management followed in the present study was analyzed individually and presented positive results in 78.9% of the cases. When laparoscopic marsupialization was chosen (2 cases), a second intervention was necessary with a percutaneous puncture in one case, and peritoneal marsupialization in another. According to data from Gruessner et al, 11 laparoscopy is a feasible technique with a success rate of 64% and should be used routinely. However, it is a limited method when the collection is anterior or supra-lateral to the graft, associated with a risk of ureteral or vascular lesion, or intestinal obstruction, possibly recurring in 35% of cases. 4, 11 The contraindication to incision or laparoscopic peritoneal marsupialization of lymphoceles is the presence of infection.
Sao

CONCLUSION
The higher frequency of acute cellular rejection found in our patients with lymphocele suggests a possible causal relation between the two conditions. Further studies should be carried out to define whether cellular rejection is a causal factor for lymphocele or if the association only relates to higher doses of corticosteroids.
